The research team, led by Allison L. Hunt and Thomas P. Conrads of the Inova Health System and Uniformed Services University together with Fei Wang and Yu Tian of AbbVie, took an unusually surgical approach to that question. Rather than grinding up whole tumor samples, the standard practice in most bulk molecular analyses, they used laser microdissection to physically separate two compartments within each tumor: the tumor epithelium, the malignant cells themselves, and the tumor-involved stromal microenvironment, the surrounding tissue of fibroblasts, immune cells, and blood vessels that shelters the cancer. Working with formalin-fixed paraffin-embedded, chemotherapy-naive specimens from twelve tumors obtained from eleven unique patients, they carved out these compartments with a laser beam guided by pathologist-annotated regions of interest.

The technical ambition of the study lies in what happened next. Each compartment was subjected to deep quantitative proteomic profiling using high-resolution liquid chromatography coupled to tandem mass spectrometry with data-independent acquisition, a strategy that systematically fragments and measures peptides across the entire sample rather than cherry-picking the most abundant ones. The result was a catalogue of 6,842 proteins co-quantified across every sample, an unusually deep measurement for microdissected archival tissue. This depth matters because proteins, not genes, are the functional machinery of cells, and measuring them directly captures the actual signaling states, metabolic programs, and inflammatory circuits operating inside each tumor compartment at the moment of surgical removal.

To classify tumors as immunologically hot or cold, the team began with pathology-assigned immune classifications, identifying six immune-hot and six immune-cold specimens based on hematoxylin and eosin stained sections, the routine stained slides pathologists examine every day. They then refined these assignments using ProteoMixture admixture deconvolution, a computational method that infers the composition of infiltrating immune cell populations from the protein signatures present in each sample. This dual approach, combining the trained eye of the pathologist with quantitative proteome deconvolution, allowed the researchers to anchor their molecular findings in histologic reality rather than treating each tumor as an undifferentiated blob of tissue.

The central finding is one of profound spatial compartmentalization. In immune-hot tumors, the stroma, not the tumor cells, carried the robust immunological signal. Stromal compartments displayed strong signatures of both innate immunity, the rapid, nonspecific first line of defense, and adaptive immunity, the antigen-specific arm involving T and B lymphocytes. The stromal profiles correlated with interferon signaling, antigen presentation machinery, and modules associated with tumor plasticity, all hallmarks of a tissue actively engaged in immune surveillance. In sharp contrast, the tumor epithelium from the same immune-hot specimens showed only weaker, predominantly innate inflammatory signaling, with heterogeneous metabolic and apoptotic signatures that varied considerably from patient to patient.

That asymmetry carries a sobering implication. The malignant cells themselves, even in tumors teeming with lymphocytes, appeared to be mounting at best a feeble inflammatory response, one that the authors suggest may be inadequate to overcome tumor-intrinsic immunosuppression or to robustly activate and engage adaptive immunity. In other words, the cancer cells were not cooperating with the immune cells camped at their borders. Immune infiltration, the study concludes, does not by itself predict effective antitumor immunity in triple-negative breast cancer. A tumor can look hot on a slide and still be functionally cold where it matters most, at the interface between the malignant cell and the immune system trying to destroy it.

The pathway-level analysis added further texture to this picture. The researchers integrated their proteomic data with gene module signatures derived from previously published single-cell RNA sequencing data from twenty-six breast cancers, including ten triple-negative tumors, allowing them to map protein-level changes onto cell-type-specific transcriptional programs. They found compartment-specific and immune-status-specific alterations in mTOR signaling, a central growth-control pathway. PI3K/AKT/mTORC1 signaling and its downstream metabolic programs were largely enriched in immune-hot stroma, suggesting that the inflamed stromal compartment is not merely a passive bystander but a metabolically active participant in the tumor ecosystem. Meanwhile, immune-cold tumors were enriched for mitotic and cell cycle progression pathways, consistent with a phenotype dominated by relentless proliferation rather than inflammatory crosstalk.

These findings arrive at a moment when the field is rethinking how it evaluates the immune response to solid tumors. Immune checkpoint inhibitors targeting PD-1 and PD-L1 have transformed treatment for a subset of triple-negative breast cancer patients, particularly those whose tumors express PD-L1 or carry high tumor-infiltrating lymphocyte counts. But the new data suggest that such histologic and single-marker assessments may be misleading. A stroma crowded with immune cells exhibiting interferon and antigen presentation signatures is not the same as a tumor epithelium that has surrendered to immune attack. Therapies, the authors argue, must target both the stromal immune dysfunction that prevents effective infiltration and activation, and the tumor-intrinsic resistance mechanisms that allow malignant cells to ignore or suppress whatever immune pressure does reach them.

The methodological lesson may prove as influential as the biological one. Laser microdissection of archival formalin-fixed paraffin-embedded tissue, combined with deep data-independent acquisition proteomics and computational immune deconvolution, transforms the humble pathology slide into a spatially resolved molecular map. Because FFPE blocks are stored in every hospital pathology department in the world, this workflow could be applied retroactively to thousands of tumors from completed clinical trials, asking retrospectively which patients responded to immunotherapy and how their tumor and stromal proteomes differed from those of nonresponders. The study was partially funded by AbbVie, and several authors are company employees, a detail that underscores the pharmaceutical industry’s growing interest in spatial proteomics as a tool for designing combination therapies that pair checkpoint inhibitors with agents targeting stromal signaling, metabolic reprogramming, or innate immune pathways such as NF-kappaB and toll-like receptor signaling.

For patients with triple-negative breast cancer, the immediate clinical impact of this study is not a new drug but a new map, one that shows immunologists precisely where the battle lines are drawn within a tumor. The stroma emerges as the true theater of the immune response, rich with innate and adaptive machinery, while the epithelial compartment harbors metabolic and cell-cycle programs that may explain why immune presence so often fails to become immune destruction. If future therapies can be engineered to convert that stromal inflammation into genuine epithelial engagement, perhaps by combining checkpoint blockade with agents that flip tumor cells from proliferative, immunologically silent programs into inflammatory, antigen-presenting ones, the promise of immunotherapy for this aggressive disease may finally extend beyond the fortunate few. The study is a reminder that in cancer biology, as in real estate, everything depends on location.

Subject of Research: Histology-resolved proteomic characterization of the tumor immune microenvironment in triple-negative breast cancer

Article Title: Histology resolved proteomic characterization of the triple negative breast cancer tumor immune microenvironment

Article References: Hunt, A. L., Wang, F., Abulez, T., Wang, X., Cui, B., Jin, L., Schejbal, J., Coberly, S., Ogata, J. D., Wilson, K. N., Conrads, K. A., Hood, B. L., Bateman, N. W., Uziel, T., Samayoa, J. A., Conrads, T. P., & Tian, Y. (2026). Histology resolved proteomic characterization of the triple negative breast cancer tumor immune microenvironment. Clinical Proteomics. https://doi.org/10.1186/s12014-026-09629-w

Image Credits: AI Generated

DOI: 10.1186/s12014-026-09629-w

Keywords: triple-negative breast cancer, tumor microenvironment, proteomics, laser microdissection, mass spectrometry, tumor stroma, immune checkpoint inhibitors, mTOR signaling, tumor-infiltrating lymphocytes, spatial proteomics, cancer immunotherapy, FFPE tissue

The study, led by Dennis Friedel, Rhaissa Ribeiro da Silva, Felix Sahm and Philipp Sievers of University Hospital Heidelberg together with collaborators across the German Cancer Research Center, set out to answer a deceptively simple question: can proteomic and phosphoproteomic profiling of ordinary archived tissue recover biologically meaningful signaling information that complements established molecular diagnostics? The researchers focused on ten cases of IDH-wildtype glioblastoma, the most aggressive adult brain tumor, split evenly between five tumors carrying EGFR amplification — one of the most frequent and well-characterized genomic alterations in this disease — and five without it. Every tumor had already undergone complete diagnostic workup, including DNA methylation profiling on the Infinium EPIC array with classification by the Heidelberg Brain Tumor Classifier and targeted sequencing of 220 CNS tumor genes, providing a rigorous genomic and epigenomic reference against which the new protein-level data could be judged.

The technical achievement underlying the study lies in how the tissue was prepared. Formalin fixation and paraffin embedding have long been the nemesis of proteomics, because cross-linking and wax infiltration make proteins difficult to extract. The Heidelberg team applied an optimized plate-based workflow that dispensed with conventional xylene deparaffinization altogether. Tiny tissue punches were placed in a 96-well plate with sodium dodecyl sulfate and magnetic beads, then processed in a BeatBox tissue homogenizer, where an alternating magnetic field drives the beads to mechanically shatter tissue and surrounding paraffin. Four cycles of ten minutes of bead-based disruption alternated with twenty minutes of heating at 95 degrees Celsius liberated the proteins, which were then cleaned up and digested using an automated single-pot solid-phase-enhanced sample preparation, or SP3, workflow on a liquid-handling robot, with 55 micrograms of protein input per sample.

Phosphopeptide enrichment was performed with iron-NTA cartridges on an automated platform before analysis on an Orbitrap Exploris 480 mass spectrometer. Global proteomes were measured using a 90-minute data-independent acquisition method, while phosphoproteomes used data-dependent acquisition, with rigorous quality controls including an MCF7 reference sample processed alongside the tumors and regular injections of a HeLa peptide standard to monitor instrument stability. The results were striking: global profiling identified a median of 7,647 proteins per tumor, with 5,417 proteins detected in all ten samples. The phosphoproteomic analysis reached a total of 13,467 phosphosites, with a cohort median of 5,457 confidently localized sites per sample, and 1,233 phosphosites reproducibly found in every single tumor. Comparable intensity distributions across samples confirmed that the quantification was robust and consistent.

To interpret phosphorylation correctly, the researchers made a crucial methodological choice: phosphosite intensities were adjusted by subtracting the measured abundance of the corresponding protein from the matched global proteome. This protein-abundance adjustment helps ensure that differences in phosphosite levels reflect genuine changes in phosphorylation state rather than simply more or less of the underlying protein being present. With this adjustment in place, the team asked whether EGFR amplification left a detectable signature on the phosphoproteome — effectively using a known genomic alteration as a biological benchmark for the new technology.

The answer was yes, but with an important nuance. Principal component analysis of the adjusted phosphoproteomic data showed only partial separation between the two groups, with EGFR amplification status significantly associated with the first principal component, which accounted for 29.9 percent of total variance. Differential analysis identified 443 phosphosites meeting predefined exploratory criteria, and among the sites enriched in EGFR-amplified tumors were two phosphorylation sites on the EGFR receptor itself, Y1110 and Y1197, which remained enriched even after adjustment for protein abundance — a biologically coherent finding given the known signaling role of the amplified receptor. Kinase-substrate enrichment analysis, which infers kinase activity from the coordinated behavior of annotated substrate sites, revealed higher activity of EGFR together with SRC-family kinases including YES1, FYN, SRC, LCK and LYN in the amplified tumors, while kinases such as PRKACA, PRKG1, MAPKAPK2 and PDPK1 showed lower inferred activity in that group.

That nuance — substantial overlap between the groups despite the clear genomic difference — may be the study’s most conceptually significant message. Two tumors can carry the same driver alteration yet differ markedly in how that alteration is expressed at the level of downstream signaling. Genomics establishes that a driver is present; phosphorylation patterns reveal whether and how its pathway is actually being used. The authors argue that this makes phosphoproteomics an orthogonal functional layer that complements, rather than duplicates, genomic and epigenomic classification. The global proteome told a parallel story: EGFR protein itself was more abundant in amplified tumors, E2F target programs were enriched in that group, while non-amplified tumors showed enrichment of stress-, immune- and microenvironment-associated programs including hypoxia, interferon-gamma response, complement and apoptosis signaling.

To show how this might work in practice, the team built a prototype research-use-only report for one representative EGFR-amplified tumor, generated entirely from that single sample without reference to the rest of the cohort. The report combined analytical quality-control metrics with pathway-level enrichment and representative phosphosites, grouped into therapeutically relevant signaling categories such as EGFR/ERBB, RAS–RAF–MEK–ERK/MAPK, PI3K–AKT–mTOR and VEGF-associated signaling, with sites including EGFR Y869 and Y1197 supporting the pathway-level findings. The authors stress that this report is a demonstration of a potential reporting framework, not a validated diagnostic or therapeutic readout, and implies nothing about drug sensitivity.

The broader context makes the approach timely. Large-scale proteogenomic studies of glioblastoma have already shown that signaling states undergo substantial post-translational remodeling during tumor evolution, meaning functional state cannot be inferred from genomic alterations alone. Elsewhere in oncology, phosphoproteomic profiling has identified patient-specific drug targets in cholangiocarcinoma and defined clinically distinct subtypes with actionable vulnerabilities in hepatocellular carcinoma. In neuro-oncology, the N2M2/NOA-20 umbrella trial has already demonstrated the clinical value of functional pathway assessment, selecting glioblastoma patients with activated mTOR signaling — judged by phospho-mTOR staining — for treatment with temsirolimus. Multiplexed phosphoproteomics could in principle extend such strategies by assessing many signaling pathways simultaneously, though the authors caution that prospective validation and clinically applicable thresholds will be required.

Significant hurdles remain before this technology reaches the clinic. The study cohort comprised only ten tumors, so individual phosphosites and inferred kinase activities must be treated as hypothesis-generating rather than candidate biomarkers. Bulk tissue analysis cannot resolve the spatial and subclonal heterogeneity that defines glioblastoma, and the protein-abundance adjustment, while informative, does not constitute a direct measurement of phosphorylation stoichiometry. Kinase-substrate enrichment infers activity from annotated substrate behavior rather than measuring enzymatic activity directly. Analytical complexity, infrastructure requirements and the cost of mass spectrometry will likely confine the approach to selected clinical and translational settings for now, and standardization of tissue processing, pipelines, thresholds and reporting will be essential for broader implementation. Nevertheless, the core demonstration stands: routine FFPE archive tissue, long valued primarily for morphology and DNA, also preserves a readable record of the tumor’s active signaling life. Integrating that functional layer with genomic and epigenomic diagnostics could eventually give neuro-oncologists a more complete picture — connecting who a tumor is with what it is actually doing.

Subject of Research: Proteomic and phosphoproteomic profiling of archived FFPE glioblastoma tissue to complement genomic and epigenomic CNS tumor diagnostics

Article Title: Functional proteomic and phosphoproteomic profiling of routine FFPE CNS tumor tissue complements genomic and epigenomic characterization

Article References: Friedel, D., da Silva, R. R., Ahmed, I. A., Wolff, B. M., Neuerburg, A., Irsevic, R., Ahmadi, S., Jayavelu, A. K., Kulozik, A. E., Witt, O., Pfister, S. M., Krieg, S. M., Wick, W., von Deimling, A., Reuss, D. E., Sahm, F., & Sievers, P. (2026). Functional proteomic and phosphoproteomic profiling of routine FFPE CNS tumor tissue complements genomic and epigenomic characterization. Acta Neuropathologica, 152(1), Article 42. https://doi.org/10.1007/s00401-026-03091-6

Image Credits: AI Generated

DOI: 10.1007/s00401-026-03091-6

Keywords: phosphoproteomics, proteomics, FFPE tissue, glioblastoma, EGFR amplification, mass spectrometry, molecular diagnostics, CNS tumors, DNA methylation profiling, kinase signaling, precision oncology, neuropathology